Advanced in Angiosarcoma of the Scalp

Dr. Anna Pavlick

Hematology | Oncology
Weill Medical College Of Cornell
1305 York Ave, Suite 12, 
New York, NY 
Clinical Trials:Currently Recruiting for 2 Trials
Offers Telehealth
Advanced in Angiosarcoma of the Scalp
Weill Medical College Of Cornell
1305 York Ave, Suite 12, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Anna Pavlick is a Hematologist and an Oncologist in New York, New York. Dr. Pavlick is rated as an Advanced provider by MediFind in the treatment of Angiosarcoma of the Scalp. Her top areas of expertise are Melanoma, Merkel Cell Carcinoma, Melanoma of the Eye, Bone Tumor, and Gamma Knife Radiosurgery.

Her clinical research consists of co-authoring 126 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in NY
Hospital Affiliations
New York-Presbyterian Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MVP Health
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

WEILL MEDICAL COLLEGE OF CORNELL
1305 York Ave, Suite 12, New York, NY 10021

Additional Areas of Focus

Dr. Pavlick has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors
Enrollment Status: Recruiting
Publish Date: January 24, 2025
Intervention Type: Biological
Study Drugs: RP1, Nivolumab
Study Phase: Phase 2
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
Enrollment Status: Recruiting
Publish Date: June 20, 2024
Intervention Type: Drug
Study Drugs: TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel
Study Phase: Phase 1
A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC and Embedded Phase I/IIa Trial With Tumor Lysate Particle Only (TLPO) Vaccine in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence.
A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC and Embedded Phase I/IIa Trial With Tumor Lysate Particle Only (TLPO) Vaccine in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence.
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Drug
Study Drug: Tumor Lysate, Particle-Loaded, Dendritic Cell Vaccine
Study Phase: Phase 2
Phase 1/2 Study of ADI-SS PEG 20,000mw in Patients With Advanced Melanoma
Phase 1/2 Study of ADI-SS PEG 20,000mw in Patients With Advanced Melanoma
Enrollment Status: Completed
Publish Date: October 25, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Poly-ICLC Matured DC as an Adjuvant for NY-ESO-1 and Melan-A/MART-1 Peptide Vaccination Compared to Montanide® ISA-51 VG, in Study Subjects With Melanoma in Complete Clinical Remission But at High Risk of Disease Recurrence
Poly-ICLC Matured DC as an Adjuvant for NY-ESO-1 and Melan-A/MART-1 Peptide Vaccination Compared to Montanide® ISA-51 VG, in Study Subjects With Melanoma in Complete Clinical Remission But at High Risk of Disease Recurrence
Enrollment Status: Completed
Publish Date: September 15, 2022
Intervention Type: Biological
Study Drugs: DC Vaccine, Montanide Vaccine, Poly-ICLC
Study Phase: Phase 2
A Phase 2 Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody-drug Conjugate, as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
A Phase 2 Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody-drug Conjugate, as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
Enrollment Status: Terminated
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

126 Total Publications

Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma.
Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma.
Journal: Journal of Cancer
Published: May 20, 2025
Similar Doctors
Distinguished in Angiosarcoma of the Scalp
Dr. Elizabeta C. Popa
Hematology | Oncology
Distinguished in Angiosarcoma of the Scalp
Dr. Elizabeta C. Popa
Hematology | Oncology

Weill Medical College Of Cornell

1305 York Ave, Suite 12, 
New York, NY 
 (0.1 miles away)
646-962-6200
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Elizabeta Popa is a Hematologist and an Oncologist in New York, New York. Dr. Popa is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma of the Scalp. Her top areas of expertise are Colorectal Cancer, Bone Tumor, Angiosarcoma of the Scalp, and Familial Colorectal Cancer.

Advanced in Angiosarcoma of the Scalp
Dr. Mary L. Keohan
Oncology | Hematology
Advanced in Angiosarcoma of the Scalp
Dr. Mary L. Keohan
Oncology | Hematology

Memorial Solid Tumor Group

160 E 53rd St, 
New York, NY 
 (0.9 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mary Keohan is an Oncologist and a Hematologist in New York, New York. Dr. Keohan is rated as an Elite provider by MediFind in the treatment of Angiosarcoma of the Scalp. Her top areas of expertise are Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Liposarcoma, Liver Embolization, and Bone Marrow Aspiration.

Advanced in Angiosarcoma of the Scalp
Dr. Sujana Movva
Oncology | Hematology Oncology | Hematology
Advanced in Angiosarcoma of the Scalp
Dr. Sujana Movva
Oncology | Hematology Oncology | Hematology

Memorial Solid Tumor Group

1275 York Ave, 
New York, NY 
 (0.1 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sujana Movva is an Oncologist and a Hematologist Oncology provider in New York, New York. Dr. Movva is rated as an Elite provider by MediFind in the treatment of Angiosarcoma of the Scalp. Her top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Gastrointestinal Stromal Tumor, Pancreaticoduodenectomy, and Splenectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pavlick's expertise for a condition
ConditionClose
View All 22 Advanced Conditions
View All 36 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile